Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report

被引：26

作者：

Zhu, You-cai ^{[1
]}

Liao, Xing-hui ^{[2
]}

Wang, Wen-xian ^{[3
]}

Xu, Chun-wei ^{[4
]}

Zhuang, Wu ^{[5
]}

Zhong, Li-hua ^{[4
]}

Du, Kai-qi ^{[1
]}

Chen, Yan-ping ^{[4
]}

Chen, Gang ^{[4
]}

Fang, Mei-yu ^{[6
]}

机构：

[1] Zhejiang Rongjun Hosp, Dept Chest Dis Diag & Treatment Ctr, Jiaxing, Zhejiang, Peoples R China

[2] Zhejiang Rongjun Hosp, Dept Tumor Mol Lab, Jiaxing, Zhejiang, Peoples R China

[3] Zhejiang Canc Hosp, Dept Chemotherapy, 1 Banshan East St, Hangzhou 310022, Zhejiang, Peoples R China

[4] Fujian Med Univ, Canc Hosp, Fujian Prov Canc Hosp, Dept Pathol, Fuzhou, Fujian, Peoples R China

[5] Fujian Med Univ, Canc Hosp, Fujian Prov Canc Hosp, Dept Med Thorac Oncol, Fuzhou, Fujian, Peoples R China

[6] Zhejiang Canc Hosp, Dept Comprehens Med Oncol, Hangzhou, Zhejiang, Peoples R China

来源：

ONCOTARGETS AND THERAPY | 2017年 / 10卷

关键词：

lung cancer; ALK; crizotinib; small-cell lung cancer; MECHANISM; CHEMOTHERAPY; INHIBITORS;

D O I：

10.2147/OTT.S139718

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Anaplastic lymphoma kinase (ALK) rearrangement responds to ALK tyrosine kinase inhibitors (TKIs) in lung cancer. Many cases ultimately acquire resistance to crizotinib. Resistance, including ALK-dominant or ALK non-dominant, mechanisms have been described. Transformation to small-cell lung cancer is rare. Herein, we report a 49-year-old man diagnosed with adenocarcinoma, who was negative for EGFR and ALK genes as detected by reverse transcription polymerase chain reaction, and was treated with crizotinib. A new biopsy showed a small-cell lung cancer after disease progression. Then, next-generation sequencing (NGS) was carried out and detected a TP53 gene mutation, an ALK rearrangement, and no loss of the retinoblastoma gene (RB). Although a regimen for small-cell lung cancer may be one treatment option, a heterogeneous tumor may exist at the time of diagnosis and manifest during the course of disease.

引用

页码：3187 / 3192

页数：6

共 19 条

[1] Treating ALK-positive lung cancer-early successes and future challenges [J].

Camidge, D. Ross ;

Doebele, Robert C. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (05) :268-277

[2] Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma [J].

Caumont, Charline ;

Veillon, Remi ;

Gros, Audrey ;

Laharanne, Elodie ;

Begueret, Hugues ;

Merlio, Jean-Philippe .

LUNG CANCER, 2016, 92 :15-18

[3] A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib [J].

Cha, Yoon Jin ;

Cho, Byoung Chul ;

Kim, Hye Ryun ;

Lee, Hye-Jeong ;

Shim, Hyo Sup .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (05) :E55-E58

[4] Non-Small Cell Lung Cancer, Version 6.2015 Featured Updates to the NCCN Guidelines [J].

Ettinger, David S. ;

Wood, Douglas E. ;

Akerley, Wallace ;

Bazhenova, Lyudmila A. ;

Borghaei, Hossein ;

Camidge, David Ross ;

Cheney, Richard T. ;

Chirieac, Lucian R. ;

D'Amico, Thomas A. ;

Demmy, Todd L. ;

Dilling, Thomas J. ;

Dobelbower, M. Chris ;

Govindan, Ramaswamy ;

Grannis, Frederic W., Jr. ;

Horn, Leora ;

Jahan, Thierry M. ;

Komaki, Ritsuko ;

Krug, Lee M. ;

Lackner, Rudy P. ;

Lanuti, Michael ;

Lilenbaum, Rogerio ;

Lin, Jules ;

Loo, Billy W., Jr. ;

Martins, Renato ;

Otterson, Gregory A. ;

Patel, Jyoti D. ;

Pisters, Katherine M. ;

Reckamp, Karen ;

Riely, Gregory J. ;

Rohren, Eric ;

Schild, Steven E. ;

Shapiro, Theresa A. ;

Swanson, Scott J. ;

Tauer, Kurt ;

Yang, Stephen C. ;

Gregory, Kristina ;

Hughes, Miranda .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (05) :515-524

[5] Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib [J].

Fujita, Shiro ;

Masago, Katsuhiro ;

Katakami, Nobuyuki ;

Yatabe, Yasushi .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (06) :E67-E72

[6] Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer [J].

Isozaki, Hideko ;

Takigawa, Nagio ;

Kiura, Katsuyuki .

CANCERS, 2015, 7 (02) :763-783

[7] Small Cell Lung Cancer [J].

Kalemkerian, Gregory P. ;

Akerley, Wallace ;

Bogner, Paul ;

Borghaei, Hossein ;

Chow, Laura Q. M. ;

Downey, Robert J. ;

Gandhi, Leena ;

Ganti, Apar Kishor P. ;

Govindan, Ramaswamy ;

Grecula, John C. ;

Hayman, James ;

Heist, Rebecca Suk ;

Horn, Leora ;

Jahan, Thierry ;

Koczywas, Marianna ;

Loo, Billy W., Jr. ;

Merritt, Robert E. ;

Moran, Cesar A. ;

Niell, Harvey B. ;

O'Malley, Janis ;

Patel, Jyoti D. ;

Ready, Neal ;

Rudin, Charles M. ;

Williams, Charles C., Jr. ;

Gregory, Kristina ;

Hughes, Miranda .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (01) :78-98

[8] Expression of Notch1 and Numb in small cell lung cancer [J].

Kikuchi, Hajime ;

Sakakibara-Konishi, Jun ;

Furuta, Megumi ;

Yokouchi, Hiroshi ;

Nishihara, Hiroshi ;

Yamazaki, Shigeo ;

Uramoto, Hidetaka ;

Tanaka, Fumihiro ;

Harada, Masao ;

Akie, Kenji ;

Sugaya, Fumiko ;

Fujita, Yuka ;

Takamura, Kei ;

Kojima, Tetsuya ;

Harada, Toshiyuki ;

Higuchi, Mitsunori ;

Honjo, Osamu ;

Minami, Yoshinori ;

Watanabe, Naomi ;

Oizumi, Satoshi ;

Suzuki, Hiroyuki ;

Ishida, Takashi ;

Dosaka-Akita, Hirotoshi ;

Isobe, Hiroshi ;

Munakata, Mitsuru ;

Nishimura, Masaharu .

ONCOTARGET, 2017, 8 (06) :10348-10358

[9] Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors [J].

Levacq, Delphine ;

D'Haene, Nicky ;

de Wind, Roland ;

Remmelink, Myriam ;

Berghmans, Thierry .

LUNG CANCER, 2016, 102 :38-41

[10] Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-Small-cell Lung Cancer [J].

Matikas, Alexios ;

Kentepozidis, Nikolaos ;

Georgoulias, Vassilis ;

Kotsakis, Athanasios .

CLINICAL LUNG CANCER, 2016, 17 (06) :474-482

← 1 2 →